VectorY: Funding, Investors & Team (Sep 2026)
VectorY utilizes a combination of antibodies and gene therapy to create effective and long-lasting treatments for significant medical conditions that currently have limited options. The company's goal is to introduce innovative therapies to patients around the world by using advanced technologies and groundbreaking scientific ideas. Founded in August 2020 and located in the Amsterdam Science Park, VectorY operates as a fully integrated gene therapy organization with a specific focus on muscle diseases and both central nervous system and somatic disorders. Through their research and production facilities in Amsterdam, VectorY develops unique programs in collaboration with partners, utilizing their AAV-based vectorized antibody and gene therapy platform. These product candidates are built upon new vector technologies, which will enable the company to manufacture a new generation of highly scalable products in their own facilities. VectorY's manufacturing capabilities will include a state-of-the-art GMP facility in the Netherlands capable of producing suspension-based AAV viral vectors of up to 2000L for both clinical and commercial use.
VectorY has raised $138M across 1 funding round on record, the most recent a Series A of $138M announced in Nov 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
VectorY Company Profile and Key Stats
Latest funding round on record: Nov 2023.
VectorY Funding Rounds
VectorY Founders and Leadership Team
No contact details are on record for this team yet.
VectorY Funding Compared to Other Biotechnology Startups
VectorY's latest round of $138M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like VectorY in Biotechnology and Amsterdam
Companies Similar to VectorY
The Protein Brewery is a high-tech company that specializes in developing and making animal-free- based…
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral…
Onward is creating an Implantable Neuro-stimulation System (INS) that includes real-time motion feedback and…
Scinvivo is a medical technology company. Scinvivo is involved in bladder cancer medical needs. They provide…
Revyve produces animal-free food ingredients from microorganisms. The company's premium ingredients include…
Merus is dedicated to creating superior treatments for cancer patients and potentially finding a cure. Our…
Salvia BioElectronics is dedicated to creating new neuromodulation devices to help treat migraines. They are…
We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial…
QurieGen is a biotechnology company that speeds up the process of finding and creating new drugs.
Protix Biosystems is a biometrics company that offers a range of products which enable its customers to…
QDI Systems is a startup company that engages in the development of advanced imaging devices for medical…
BIMINI Biotech, a startup established in 2019 in Leiden, The Netherlands, focuses on creating groundbreaking…
VectorY Funding FAQs
What does VectorY do?
VectorY utilizes a combination of antibodies and gene therapy to create effective and long-lasting treatments for significant medical conditions that currently have limited options. The company's goal is to introduce innovative therapies to patients around the world by using advanced technologies and groundbreaking scientific ideas. Founded in August 2020 and located in the Amsterdam Science Park, VectorY operates as a fully integrated gene therapy organization with a specific focus on muscle diseases and both central nervous system and somatic disorders. Through their research and production facilities in Amsterdam, VectorY develops unique programs in collaboration with partners, utilizing their AAV-based vectorized antibody and gene therapy platform. These product candidates are built upon new vector technologies, which will enable the company to manufacture a new generation of highly scalable products in their own facilities. VectorY's manufacturing capabilities will include a state-of-the-art GMP facility in the Netherlands capable of producing suspension-based AAV viral vectors of up to 2000L for both clinical and commercial use.
How much funding has VectorY raised?
VectorY has raised $138M across 1 round on record. The most recent is a Series A of $138M announced in Nov 2023.
When did VectorY last raise funding?
VectorY's most recent funding round on record is a Series A of $138M, announced in Nov 2023.
Who founded VectorY?
FundedIQ lists Anthony Newcombe (Founder) at VectorY.
Where is VectorY headquartered?
VectorY is based in Amsterdam, Noord-Holland, Netherlands.
How many employees does VectorY have?
VectorY is in the 51-100 employee band.
How does VectorY's funding compare to other Biotechnology startups?
VectorY's latest round of $138M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's VectorY Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for VectorY is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.